Radical-Dose Image Guided Radiation Therapy in Treating Patients With Metastatic Non-small Cell Lung Cancer Undergoing Immunotherapy

Stage IV Non-Small Cell Lung Cancer Clinical Trial

Official title:

Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03176173
• Other study ID #: IRB-40088
• Secondary ID: NCI-2017-00952LU
• Status: Active, not recruiting
• Phase: N/A
• Start date: June 28, 2017
• Est. completion date: May 1, 2026

Study information

• Verified date: June 2024
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well radical-dose image guided radiation therapy works in treating patients with non-small cell lung cancer that has spread to other places in the body who are undergoing immunotherapy. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radical-dose image guided radiation therapy to patients with non-small cell lung cancer may help to improve response to immunotherapy anti-cancer treatment.

Description:

PRIMARY OBJECTIVES:

I. Determine if progression-free survival at 24 weeks with this treatment combination is improved compared to historical controls who received immunotherapy without radiation therapy.

SECONDARY OBJECTIVES:

I. Assess acute (0-6 months) and late (> 6 months) grade 3-5 toxicity. II. Assess overall survival. III. Correlate circulating tumor deoxyribonucleic acid (DNA) (ratio of post-radiation therapy [RT] to pre-RT level) with radiographic response.

IV. Correlate immune markers in peripheral blood with radiographic response.

TERTIARY OBJECTIVES:

I. Analyze progression-free survival with immune-related response criteria. II. Measure time to discontinuation of study immunotherapy agent. III. Assess patterns of progression.

OUTLINE: Patients are assigned to 1 of 2 arms.

ARM I: Patients undergo radical-dose image guided radiation therapy daily for up to 10 days (within 2 weeks) while undergoing standard of care immunotherapy.

Arm II: Patients who decline to undergo radiation therapy receive standard of care immunotherapy.

After completion of study treatment, patients are followed up at 30 days and every 6 months thereafter.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 44
• Est. completion date: May 1, 2026
• Est. primary completion date: November 24, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Has stage IV non-small cell lung cancer, or initially stage I-III disease with distant metastatic recurrence

2. Age = 18

3. Has been receiving anti-PD-1 or anti-PD-L1 immunotherapy for at least four weeks (refer to section 4.2.1)

4. Has had restaging imaging after initiation of immunotherapy, at least 4 weeks after pre-immunotherapy baseline imaging. CT or PET/CT of at least chest/upper abdomen must be performed within 4 weeks prior to registration. For patients with history of brain metastases, brain MRI or CT is required within 4 weeks of registration; for other patients brain MRI or CT is required within 12 weeks of registration. Diagnostic PET/CT performed as part of radiation simulation can be used as the restaging imaging.

5. Most recent imaging shows measurable disease as defined by RECIST 1.1

6. Evaluation by a Stanford medical oncologist must show:

1. The patient is expected to continue on immunotherapy for at least three more months

2. Imaging must show response, stable disease, or modest progression

3. If there is modest progression, the patient must be clinically stable in terms of performance status and overall disease-related symptoms

7. Has at least one extracranial tumor safely treatable with radical-dose radiation therapy and that has not been previously treated with radiation

8. ECOG performance status 0-2

9. Has the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Untreated brain metastases, if not planned to be treated in this course of radiation therapy

• Pregnancy or women of childbearing potential not willing/able to use contraception during protocol treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Stage IV Non-Small Cell Lung Cancer

Intervention

Radiation:
• Image-guided Radiation Therapy
Ablative treatment as 50 Gy in 5 or 10 fractions. Non-ablative treatment as 27 Gy in 3 fractions, or 40 Gy in 10 fractions.

Drug:
• Immunotherapy (physician's choice for standard of care immunotherapy)
Continue regular medical care immunotherapy. Other than being an anti-PD-1 or anti-PD-L1 immunotherapy, the agent, dose, and schedule is not specified by protocol.

Locations

Country	Name	City	State
United States	Stanford University, School of Medicine	Palo Alto	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Patterns of response and progression	Patterns of response and progression, including abscopal responses will be measured.	Up to 4 years
Other	Progression free survival	Evaluated with immune-related Response Criteria.	Up to 4 years
Other	Time to discontinuation of study immunotherapy agent	Time to discontinuation of study immunotherapy agent will be measured.	Up to 4 years
Primary	Progression-free survival	Defined as proportion of patients without Response Evaluation Criteria in Solid Tumors version 1.1 disease progression or death 24 weeks from date of study entry.	At 24 weeks after study entry
Secondary	Change in circulating tumor deoxyribonucleic acid levels as measured using CAncer Personalized Profiling by deep Sequencing	Will correlate with radiographic response. Plasma biomarkers (e.g. cell free deoxyribonucleic acid level) will be summarized using medians and interquartile ranges; changes in biomarkers will be assessed using the Wilcoxon signed rank test. Correlation of biomarkers with radiographic response will be evaluated using a Wilcoxon rank sum test on patients with and without the event of interest. If feasible, these analyses will be supplemented by more formal analyses with the Cox model.	Baseline up to 1 year after study entry
Secondary	Change in immune marker levels as measured from peripheral blood using flow cytometry performed by the Human Immune Monitoring Core at Stanford University	Will correlate with radiographic response.	Baseline up to 1 year after study entry
Secondary	Incidence of acute (0-6 months) and late (> 6 months) grade 3-5 toxicity	Measured with Common Terminology Criteria for Adverse Events version 4.	Up to 4 years after study entry
Secondary	Overall survival	The electronic medical record will be monitored for patient deaths.	Time from study entry to death, assessed up to 4 years after study entry